After finishing at $88.40 in the prior trading day, Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) closed at $86.28, down -2.40%. In other words, the price has decreased by -$2.12 from its previous closing price. On the day, 2604334 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of BMRN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 260.18. For the most recent quarter (mrq), Quick Ratio is recorded 1.57 and its Current Ratio is at 2.51. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on November 15, 2023, initiated with a Overweight rating and assigned the stock a target price of $100.
On October 23, 2023, Bernstein Upgraded its rating to Mkt Perform which previously was Underperform but kept the price unchanged to $82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 27 when BIENAIME JEAN JACQUES sold 1,000 shares for $90.35 per share. The transaction valued at 90,350 led to the insider holds 562,203 shares of the business.
BIENAIME JEAN JACQUES sold 15,000 shares of BMRN for $1,324,200 on Feb 09. The Director now owns 419,602 shares after completing the transaction at $88.28 per share. On Feb 08, another insider, BIENAIME JEAN JACQUES, who serves as the Director of the company, sold 15,000 shares for $89.77 each. As a result, the insider received 1,346,550 and left with 419,602 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 16.28B and an Enterprise Value of 16.30B. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 99.04, and their Forward P/E ratio for the next fiscal year is 31.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.73 while its Price-to-Book (P/B) ratio in mrq is 3.29. Its current Enterprise Value per Revenue stands at 6.74 whereas that against EBITDA is 52.64.
Stock Price History:
Over the past 52 weeks, BMRN has reached a high of $102.79, while it has fallen to a 52-week low of $76.02. The 50-Day Moving Average of the stock is 92.39, while the 200-Day Moving Average is calculated to be 89.84.
Shares Statistics:
The stock has traded on average 1.51M shares per day over the past 3-months and 1.68M shares per day over the last 10 days, according to various share statistics. A total of 188.60M shares are outstanding, with a floating share count of 185.00M. Insiders hold about 1.95% of the company’s shares, while institutions hold 98.99% stake in the company. Shares short for BMRN as of Feb 15, 2024 were 3.26M with a Short Ratio of 2.16, compared to 3.42M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.73% and a Short% of Float of 1.74%.
Earnings Estimates
Its stock is currently analyzed by 17 different market analysts. On average, analysts expect EPS of $0.33 for the current quarter, with a high estimate of $0.49 and a low estimate of $0.21, while EPS last year was $0.27. The consensus estimate for the next quarter is $0.37, with high estimates of $0.47 and low estimates of $0.23.
Analysts are recommending an EPS of between $2.08 and $1.17 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $2.83, with 20 analysts recommending between $4.91 and $1.43.
Revenue Estimates
21 analysts predict $650.4M in revenue for the current quarter. It ranges from a high estimate of $675M to a low estimate of $618.9M. As of the current estimate, Biomarin Pharmaceutical Inc.’s year-ago sales were $596.41M, an estimated increase of 9.10% from the year-ago figure.
A total of 28 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $2.92B, while the lowest revenue estimate was $2.61B, resulting in an average revenue estimate of $2.77B. In the same quarter a year ago, actual revenue was $2.42B, up 14.30% from the average estimate. Based on 26 analysts’ estimates, the company’s revenue will be $3.17B in the next fiscal year. The high estimate is $3.76B and the low estimate is $2.82B. The average revenue growth estimate for next year is up 14.50% from the average revenue estimate for this year.
